Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

The Handmaid’s Tale has introduced its fair share of unsettling figures over the years, but none have shaken things up quite ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health insurers to ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Wells Fargo said the U.S. Supreme Court’s decision to preserve no-cost coverage for preventive services marks a “win for ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Get the latest Gilead Sciences, Inc. (GILD) stock news and headlines to help you in your trading and investing decisions.